FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (AtezoTRIBE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03721653 |
Recruitment Status :
Completed
First Posted : October 26, 2018
Last Update Posted : October 12, 2023
|
Sponsor:
Gruppo Oncologico del Nord-Ovest
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Gruppo Oncologico del Nord-Ovest
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | June 15, 2021 |
Actual Study Completion Date : | August 31, 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):